AbbVie, BMS to test Rova-T combos for SCLC

AbbVie Inc. (NYSE:ABBV) and Bristol-Myers Squibb Co. (NYSE:BMY) plan to start a Phase I/II study this year of antibody-drug conjugate (ADC) Rova-T rovalpituzumab in combination with Opdivo nivolumab, and in combination with Opdivo plus Yervoy ipilimumab, to treat relapsed extensive-stage small cell lung cancer (SCLC).

Last month, CSO and EVP of R&D Michael Severino told investors that AbbVie intended to develop Rova-T in combination with PD-1 inhibitors and other immunotherapies, including approved checkpoint inhibitors (see BioCentury, June 13). ...